SBIR Phase I: Scale-up Manufacturing of Nitric Oxide Nanotechnology for Healthcare Infections

SBIR 第一阶段：用于医疗感染的一氧化氮纳米技术的放大生产

• 批准号: 1013531
• 负责人: Nathan Stasko
• 金额: $ 14.08万
• 依托单位: Novan, Inc.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=1013531&HistoricalAwards=false
• 关键词: SBIR; Phase; Scale; up; Manufacturing

This Small Business Innovation Research (SBIR) Phase I project aims to develop a scale-up manufacturing process of nitric oxide-releasing silica nanoparticles. The main challenge is controlling the nanoparticle crystal size while maintaining high levels of nitric oxide storage. In this project, critical process parameters including reactant addition rate, reaction temperature and mixing rate will be studied. The Balanced-Nucleation and Growth (BNG) Model will be utilized to transform process data into predictors of controlled particle size.The broader/commercial impact of this project will be the potential to provide large-volume nitric oxide-releasing silica nanoparticles for placement in products aimed at the prevention and treatment of infectious diseases. Availability of large-quantity nitric oxide-releasing silica nanoparticles is important to combat the rising number of nosocomial infections. However, the necessary scale-up technology to manufacture nitric oxide-releasing silica nanoparticles is not available. This project is expected to provide the processes to manufacture large quantities of nitric oxide-releasing silica nanoparticles for anti-infective product development.

这个小型企业创新研究(SBIR)第一阶段项目旨在开发一种大规模生产一氧化氮释放二氧化硅纳米颗粒的工艺。主要的挑战是控制纳米颗粒的晶体尺寸，同时保持高水平的一氧化氮存储。在本项目中，将研究包括反应物添加速度、反应温度和混合速度在内的关键工艺参数。平衡成核与生长(BNG)模型将被用来将过程数据转换为可控颗粒大小的预测值。该项目的更广泛/商业影响将是提供大量释放一氧化氮的二氧化硅纳米颗粒用于预防和治疗传染病的产品的潜力。大量释放一氧化氮的二氧化硅纳米颗粒的可获得性对于抗击不断上升的医院感染数量至关重要。然而，制造释放一氧化氮的二氧化硅纳米颗粒所需的放大技术尚不存在。该项目有望为抗感染产品开发提供制造大量释放一氧化氮的二氧化硅纳米颗粒的工艺。